MGRX insider trade: director reports 125,000-share stock sale

Rhea-AI Filing Summary

Mangoceuticals, Inc. director reports stock sale in Form 4 filing. A board member of Mangoceuticals, Inc. (MGRX) disclosed the sale of 125,000 shares of common stock on 11/19/2025, reported under transaction code "S" for a sale. The weighted average sale price was $1.223 per share.

These shares were sold in multiple trades at prices ranging from $1.195 to $1.2465 per share. Following this transaction, the reporting person beneficially owns 3,334 shares of Mangoceuticals common stock in direct ownership.

Insider Trade Summary

Net Seller: 125,000 shares

Net Sell 1 txn

Insider Hamilton Alex P.

Role Director

Sold 125,000 shs ($153K)

Type	Security	Shares	Price	Value
Sale	Common Stock	125,000	$1.223	$153K

Holdings After Transaction: Common Stock — 3,334 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $1.195 to $1.2465, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/26/2025 - 04:30 PM Learn about SEC filing dates

FAQ

What did the Mangoceuticals (MGRX) director report in this Form 4?

The director reported selling 125,000 shares of Mangoceuticals, Inc. (MGRX) common stock on 11/19/2025 in an open-market sale.

At what price were the MGRX shares sold in this insider transaction?

The reported weighted average sale price was $1.223 per share, with individual trades executed between $1.195 and $1.2465 per share.

How many Mangoceuticals (MGRX) shares does the director own after the sale?

After the reported sale, the director beneficially owns 3,334 shares of Mangoceuticals common stock in direct ownership.

What transaction code is shown for this Mangoceuticals Form 4 event?

The transaction is labeled with code "S", which indicates an open-market or private sale of non-derivative securities.

Was this Mangoceuticals (MGRX) sale executed in a single trade?

No. The sale was executed in multiple trades at prices ranging from $1.195 to $1.2465 per share, with the filing reporting a weighted average price.

Who signed the Mangoceuticals (MGRX) Form 4 for this insider transaction?

The Form 4 was signed by /s/ Alex P. Hamilton on 11/26/2025, as the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton Alex P.

(Last) (First) (Middle)

C/O MANGOCEUTICALS, INC.

15110 N. DALLAS PARKWAY, SUITE 600

(Street)

DALLAS TX 75248

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MANGOCEUTICALS, INC. [ MGRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/19/2025		S		125,000	D	$1.223(1)	3,334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.195 to $1.2465, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Alex P. Hamilton	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.